CARLOS JESUS
DUEÑAS GUTIERREZ
PROFESOR ASOCIADO CIENCIAS DE LA SALUD
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Príncipe de Asturias (8)
2024
-
Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study
Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
2015
-
Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16
-
Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2007
-
Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables
Medicina Clinica, Vol. 129, Núm. 10, pp. 361-365
2006
-
Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: A cross-sectional study
Cardiovascular Diabetology, Vol. 5